Lycia Therapeutics Statistics
Total Valuation
LYCA has a market cap or net worth of $1.91 billion. The enterprise value is $1.76 billion.
Important Dates
The next estimated earnings date is Friday, December 4, 2026, after market close.
| Earnings Date | Dec 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LYCA has 57.68 million shares outstanding.
| Current Share Class | 57.68M |
| Shares Outstanding | 57.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 10.55% |
| Float | 33.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 430.10 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 397.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.60, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.60 |
| Quick Ratio | 12.26 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,300.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.16% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -23.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $143,065 |
| Profits Per Employee | -$968,774 |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -249,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.92 |
| Average Volume (20 Days) | 340,190 |
Short Selling Information
The latest short interest is 304,185, so 0.53% of the outstanding shares have been sold short.
| Short Interest | 304,185 |
| Short Previous Month | n/a |
| Short % of Shares Out | 0.53% |
| Short % of Float | 0.90% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, LYCA had revenue of $4.44 million and -$30.03 million in losses. Loss per share was -$2.09.
| Revenue | 4.44M |
| Gross Profit | 12.93M |
| Operating Income | -33.81M |
| Pretax Income | -30.28M |
| Net Income | -30.03M |
| EBITDA | -32.84M |
| EBIT | -33.81M |
| Loss Per Share | -$2.09 |
Full Income Statement Balance Sheet
The company has $148.09 million in cash and investments and $3.16 million in debt, with a net cash position of $144.93 million or $2.51 per share.
| Cash & Investments | 148.09M |
| Total Debt | 3.16M |
| Net Cash | 144.93M |
| Net Cash Per Share | $2.51 |
| Equity (Book Value) | 144.92M |
| Book Value Per Share | -9.02 |
| Working Capital | 117.58M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$33.75 million and capital expenditures -$34,000, giving a free cash flow of -$33.79 million.
| Operating Cash Flow | -33.75M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 974,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.79M |
| FCF Per Share | -$0.59 |
Full Cash Flow Statement Margins
| Gross Margin | 291.48% |
| Operating Margin | -762.32% |
| Pretax Margin | -682.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LYCA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.32% |
| FCF Yield | -1.77% |
Analyst Forecast
The average price target for LYCA is $54.00, which is 63.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $54.00 |
| Price Target Difference | 63.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LYCA has an Altman Z-Score of -1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1 |
| Piotroski F-Score | n/a |